Oppenheimer Initiates Coverage on PolyPid with Outperform Rating and $10 Price Target
PolyPid (PYPD) shares saw upward momentum following the initiation of coverage by Oppenheimer. The investment bank issued an 'Outperform' rating for the Israeli biopharmaceutical company, setting a price target of $10 per share. The positive outlook is driven by anticipation surrounding the company's lead asset, D-PLEX100. Investors are closely monitoring a key upcoming milestone on November 28, which serves as a critical target action date for the development and progress of this primary asset.
Tickers: $PYPD
Topics: Analyst Initiation Biotechnology Stock Price Movement